APOLLO - Upper Midwest

摘要 接受非裔美国人已故捐赠者肾脏移植的患者情况更糟 结果比他们接受白人已故捐赠者的器官的同行要好。广度 这是由于非洲裔美国人捐赠者中存在高危APOL1基因类型所致 未知。最近的几项研究发现，高危载脂蛋白1与 基因分型和移植失败，但这些都是基于相对较少的事件，已经发生了 主要来自几个大型中心，还没有分析捐赠者和接受者对。建议数 研究将调查肾捐赠者的APOL1状态与受者的关系 结果。我们还将研究估计APLO1状态对活体供者结局的影响。 我们已经组建了一个由6个器官采购组织组成的财团，涵盖7个 上中西部各州，123家康复医院，25个移植中心和合作者 在移植手术中，移植肾病学、流行病学和遗传学为实现这些目标而努力。 这些发现将使我们更好地理解高危人群的存在带来的影响。 受者和活体供者中的APOL1变异。这些数据是提供信息所需的 受者、潜在的活体捐赠者及其照顾者的决策。相对关系和 与高危APOL1变异相关的临床重大事件的绝对风险将是 比以前的研究更精确地估计，从而做出更明智的决定 关于接受特定器官移植的问题。

ABSTRACT Recipients of a kidney transplant from an African-American deceased donor have worse outcomes than their counterparts receiving an organ from a White deceased donor. The extent to which this is due to the presence of high-risk APOL1 genotypes in African-American donors is unknown. Several recent studies have found a positive association between high-risk APOL1 genotypes and graft failure, but these have been based on relatively few events, have come primarily from a few large centers, and have not analyzed donor-recipient pairs. The proposed studies will investigate the association of a kidney donor's APOL1 status with recipient outcomes. We will also study estimate the impact of APLO1 status on living donor outcomes. We have assembled a consortium including 6 organ procurement organizations covering 7 states in the Upper Midwest, 123 recovering hospitals, 25 transplant centers and collaborators in transplant surgery, transplant nephrology, epidemiology and genetics to achieve these goals. These findings will provide a greater understanding of the impact of the presence of high-risk APOL1 variants in both recipients and living donors. These data are needed for informed decision-making for recipients, potential living donors, and their caregivers. Both the relative and absolute risk of clinically significant events associated with high-risk APOL1 variants will be estimated with much greater precision that previous studies, allowing more informed decisions on acceptance of specific organs for transplantation.